Vimseltinib may be promising in treating symptomatic tenosynovial giant cell tumour
1. Tumor response rate at 25 weeks was significantly greater in vimseltinib than placebo. 2. Most adverse events were mild-to-moderate ...
Tag: Tenosynovial giant cell tumour (TGCT)